These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 19089508)
1. Home buprenorphine/naloxone induction in primary care. Lee JD; Grossman E; DiRocco D; Gourevitch MN J Gen Intern Med; 2009 Feb; 24(2):226-32. PubMed ID: 19089508 [TBL] [Abstract][Full Text] [Related]
2. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872 [TBL] [Abstract][Full Text] [Related]
3. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
5. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting. Amato P Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre. Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
10. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Rosado J; Walsh SL; Bigelow GE; Strain EC Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480 [TBL] [Abstract][Full Text] [Related]
11. Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. Wang EA; Moore BA; Sullivan LE; Fiellin DA J Gen Intern Med; 2010 Jul; 25(7):670-4. PubMed ID: 20213205 [TBL] [Abstract][Full Text] [Related]
12. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? Srivastava A; Kahan M; Nader M Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795 [TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals. Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527 [TBL] [Abstract][Full Text] [Related]
14. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Amass L; Kamien JB; Mikulich SK Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282 [TBL] [Abstract][Full Text] [Related]
15. A trial of integrated buprenorphine/naloxone and HIV clinical care. Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305 [TBL] [Abstract][Full Text] [Related]
16. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence. Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114 [TBL] [Abstract][Full Text] [Related]
17. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine. Chhabra N; Aks SE Am J Emerg Med; 2020 Mar; 38(3):691.e3-691.e4. PubMed ID: 31753622 [TBL] [Abstract][Full Text] [Related]
18. A Retrospective Evaluation of Inpatient Transfer from High-Dose Methadone to Buprenorphine Substitution Therapy. Oretti R J Subst Abuse Treat; 2015 Oct; 57():102-5. PubMed ID: 26048187 [TBL] [Abstract][Full Text] [Related]
19. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Caldiero RM; Parran TV; Adelman CL; Piche B Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087 [TBL] [Abstract][Full Text] [Related]
20. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. Jain K; Jain R; Dhawan A J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]